364 related articles for article (PubMed ID: 25162417)
21. CD40-induced signaling in human endothelial cells results in mTORC2- and Akt-dependent expression of vascular endothelial growth factor in vitro and in vivo.
Dormond O; Contreras AG; Meijer E; Datta D; Flynn E; Pal S; Briscoe DM
J Immunol; 2008 Dec; 181(11):8088-95. PubMed ID: 19018001
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of mTOR ameliorates bleomycin-induced pulmonary fibrosis by regulating epithelial-mesenchymal transition.
Han Q; Lin L; Zhao B; Wang N; Liu X
Biochem Biophys Res Commun; 2018 Jun; 500(4):839-845. PubMed ID: 29704504
[TBL] [Abstract][Full Text] [Related]
23. Differential effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway in acute lymphoblastic leukemia.
Badura S; Tesanovic T; Pfeifer H; Wystub S; Nijmeijer BA; Liebermann M; Falkenburg JH; Ruthardt M; Ottmann OG
PLoS One; 2013; 8(11):e80070. PubMed ID: 24244612
[TBL] [Abstract][Full Text] [Related]
24. Periostin responds to mechanical stress and tension by activating the MTOR signaling pathway.
Rosselli-Murai LK; Almeida LO; Zagni C; Galindo-Moreno P; Padial-Molina M; Volk SL; Murai MJ; Rios HF; Squarize CH; Castilho RM
PLoS One; 2013; 8(12):e83580. PubMed ID: 24349533
[TBL] [Abstract][Full Text] [Related]
25. RhoA modulates signaling through the mechanistic target of rapamycin complex 1 (mTORC1) in mammalian cells.
Gordon BS; Kazi AA; Coleman CS; Dennis MD; Chau V; Jefferson LS; Kimball SR
Cell Signal; 2014 Mar; 26(3):461-7. PubMed ID: 24316235
[TBL] [Abstract][Full Text] [Related]
26. mTORC2 is required for proliferation and survival of TSC2-null cells.
Goncharova EA; Goncharov DA; Li H; Pimtong W; Lu S; Khavin I; Krymskaya VP
Mol Cell Biol; 2011 Jun; 31(12):2484-98. PubMed ID: 21482669
[TBL] [Abstract][Full Text] [Related]
27. The preclinical evaluation of the dual mTORC1/2 inhibitor INK-128 as a potential anti-colorectal cancer agent.
Li C; Cui JF; Chen MB; Liu CY; Liu F; Zhang QD; Zou J; Lu PH
Cancer Biol Ther; 2015; 16(1):34-42. PubMed ID: 25692620
[TBL] [Abstract][Full Text] [Related]
28. Biochanin-A ameliorates pulmonary fibrosis by suppressing the TGF-β mediated EMT, myofibroblasts differentiation and collagen deposition in in vitro and in vivo systems.
Andugulapati SB; Gourishetti K; Tirunavalli SK; Shaikh TB; Sistla R
Phytomedicine; 2020 Nov; 78():153298. PubMed ID: 32781391
[TBL] [Abstract][Full Text] [Related]
29. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of 14-3-3 binding to Rictor of mTORC2 for Akt phosphorylation at Ser473 is regulated by selenoprotein W.
Jeon YH; Park YH; Kwon JH; Lee JH; Kim IY
Biochim Biophys Acta; 2013 Oct; 1833(10):2135-42. PubMed ID: 23680186
[TBL] [Abstract][Full Text] [Related]
31. Rictor/mammalian target of rapamycin complex 2 promotes macrophage activation and kidney fibrosis.
Ren J; Li J; Feng Y; Shu B; Gui Y; Wei W; He W; Yang J; Dai C
J Pathol; 2017 Aug; 242(4):488-499. PubMed ID: 28585302
[TBL] [Abstract][Full Text] [Related]
32. Sunitinib, a Small-Molecule Kinase Inhibitor, Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice.
Huang X; Wang W; Yuan H; Sun J; Li L; Wu X; Luo J; Gu Y
Tohoku J Exp Med; 2016 Aug; 239(4):251-61. PubMed ID: 27439438
[TBL] [Abstract][Full Text] [Related]
33. The mTORC2 complex regulates terminal differentiation of C2C12 myoblasts.
Shu L; Houghton PJ
Mol Cell Biol; 2009 Sep; 29(17):4691-700. PubMed ID: 19564418
[TBL] [Abstract][Full Text] [Related]
34. Transmembrane Inhibitor of RICTOR/mTORC2 in Hematopoietic Progenitors.
Lee D; Sykes SM; Kalaitzidis D; Lane AA; Kfoury Y; Raaijmakers MH; Wang YH; Armstrong SA; Scadden DT
Stem Cell Reports; 2014 Nov; 3(5):832-40. PubMed ID: 25418727
[TBL] [Abstract][Full Text] [Related]
35. Equivalent benefit of rapamycin and a potent mTOR ATP-competitive inhibitor, MLN0128 (INK128), in a mouse model of tuberous sclerosis.
Guo Y; Kwiatkowski DJ
Mol Cancer Res; 2013 May; 11(5):467-73. PubMed ID: 23386687
[TBL] [Abstract][Full Text] [Related]
36. Functional Role of mTORC2 versus Integrin-Linked Kinase in Mediating Ser473-Akt Phosphorylation in PTEN-Negative Prostate and Breast Cancer Cell Lines.
Lee SL; Chou CC; Chuang HC; Hsu EC; Chiu PC; Kulp SK; Byrd JC; Chen CS
PLoS One; 2013; 8(6):e67149. PubMed ID: 23840605
[TBL] [Abstract][Full Text] [Related]
37. Targeting of mTORC2 may have advantages over selective targeting of mTORC1 in the treatment of malignant pheochromocytoma.
Zhang X; Wang X; Xu T; Zhong S; Shen Z
Tumour Biol; 2015 Jul; 36(7):5273-81. PubMed ID: 25666752
[TBL] [Abstract][Full Text] [Related]
38. PRR5L degradation promotes mTORC2-mediated PKC-δ phosphorylation and cell migration downstream of Gα12.
Gan X; Wang J; Wang C; Sommer E; Kozasa T; Srinivasula S; Alessi D; Offermanns S; Simon MI; Wu D
Nat Cell Biol; 2012 May; 14(7):686-96. PubMed ID: 22609986
[TBL] [Abstract][Full Text] [Related]
39. Myeloid-specific Rictor deletion induces M1 macrophage polarization and potentiates in vivo pro-inflammatory response to lipopolysaccharide.
Festuccia WT; Pouliot P; Bakan I; Sabatini DM; Laplante M
PLoS One; 2014; 9(4):e95432. PubMed ID: 24740015
[TBL] [Abstract][Full Text] [Related]
40. Depletion of Rictor, an essential protein component of mTORC2, decreases male lifespan.
Lamming DW; Mihaylova MM; Katajisto P; Baar EL; Yilmaz OH; Hutchins A; Gultekin Y; Gaither R; Sabatini DM
Aging Cell; 2014 Oct; 13(5):911-7. PubMed ID: 25059582
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
